Single Cell Technology and Open Monoclonal Technology announce human antibody discovery and development collaboration
3 December 2012
San Jose and Palo Alto, CA, December 3, 2012
Single Cell Technology, Inc. (SCT) and Open Monoclonal Technology, Inc. (OMT) today announced a new collaboration where OMT will use its OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT. SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS). SCT will advance and partner the program and share the economics with OMT depending on the stage of development. SCT will also have an option to develop and commercialize selected products resulting from the research.
Dr. Chun-Nan Chen, Founder and CEO of SCT said: “This partnership with OMT will demonstrate the value of delineating the antibody repertoire of the humoral response by NGS early during antibody discovery. The human immune gene sequences engineered into OmniRat by OMT will work perfectly with SCT’s massive screening and sequencing platform. We anticipate exciting results.”
Dr. Roland Buelow, Founder and CEO of OMT, continued: “We are pleased to collaborate with SCT to capture the synergies of our complementary antibody discovery technologies. This collaboration continues OMT’s process of participating in as many opportunities for development of human therapeutic antibodies as possible and establishing OmniRat as a leading transgenic animal brand.”
ABOUT SINGLE CELL TECHNOLOGY, INC.
Single Cell Technology, Inc. (SCT) has pioneered a new approach to analysing antibodies and mRNA from individual antibody secreting cells. Antibodies are rapidly screened against multiple molecules to measure their affinity and specificity and mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS) technology and correctly paired. In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. Founders Chun-Nan Chen and Jim Bowlby integrated advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.
ABOUT OPEN MONOCLONAL TECHNOLOGY, INC.
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – naturally optimized human antibodies™. OMT has developed OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat is based on an improved understanding of B cell development and a novel approach to inactivation of endogenous antibody expression. These transgenic animals make antibodies as efficiently as wild type animals. OmniRat is a new and proprietary technology with unrestricted development options for fully human monoclonal antibodies worldwide, for all targets and indications.
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.